Feiba

Feiba (Factor VIII Inhibitor Bypassing Fraction) is a medication used to manage bleeding episodes in patients with hemophilia who have inhibitors. This intravenous treatment helps to control bleeding by bypassing the need for Factor VIII.

Feiba is primarily used to manage bleeding episodes in patients with hemophilia A or B who have developed inhibitors to Factor VIII or IX. These inhibitors can make standard treatments ineffective, and Feiba provides an alternative to help control bleeding. It is often used in situations where bleeding is not responding to other treatments.

Feiba works by providing a bypassing agent that helps to form clots in the blood, which can help to stop bleeding. Common effects may include localized reactions at the injection site, such as redness or swelling. Some patients may also experience systemic reactions like fever or chills.

Feiba should be administered under the supervision of a healthcare professional. It is important to monitor for signs of allergic reactions or other adverse effects. Patients with a history of thrombosis or disseminated intravascular coagulation (DIC) should use Feiba with caution.

Feiba may interact with other medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.